Nivolumab-relatlimab adjuvant therapy for stage III-IV resected melanoma

Nivolumab-relatlimab is currently clinical development for the adjuvant treatment of patients with resected stage III-IV melanoma. Melanoma is a type of skin cancer. The stage of a cancer tells how big it is and how far it has spread. Stage III melanomas are regional, meaning the cancer has spread beyond the primary tumour (local) to the closest lymph nodes, but not too distant sites. Stage IV (metastatic) melanomas involve distant sites from the original tumour, which can include the lungs and the brain. Adjuvant therapy (treatment given after the main therapy, e.g. surgery), can reduce the risk of micrometastes following surgery, which can limit/prevent further progression of melanoma in these patients.